Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study.

ABSTRACT:

Background

hPG₈₀ (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO centralized case-control study (NCT03787056) was designed to prospectively evaluate the diagnostic utility of hPG₈₀ in patients with 16 different types of cancer.

Methods

hPG₈₀ levels were measured in 421 patients with 16 newly diagnosed cancers (median age 65.6 years old) using the DxPG80.Lab kit (Biodena Care). The diagnostic performance of hPG₈₀ (the primary endpoint) was assessed by comparing baseline hPG₈₀ levels in cancer patients with those of 330 asymptomatic aged-matched healthy sub

SUBMITTER: You B 

PROVIDER: S-EPMC12218953 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature